^
Association details:
| Biomarker: | DLL3 overexpression |
|---|---|
| Cancer: | Neuroendocrine Tumor |
| Drug: | Rova-T (rovalpituzumab tesirine) (DNA replication inhibitor, DLL3-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing, advanced solid tumors.
Published date:
05/25/2020
Excerpt:
...The study enrolled 200 patients; 101 had NECs (large cell NEC [n=13], neuroendocrine prostate cancer [n=21], high-grade gastroenteropancreatic NEC [n=36]...The objective response rate (ORR) was 11% (21/200): 14 had NEC, 2 had MM, 2 had MTC, 2 had small cell carcinoma (SCC) not of lung origin (all partial responses), and 1 had GBM (complete response). In patients with NECs given 0.3 mg/kg, ORR, clinical benefit rate, and progression-free survival trended in favor of those with high DLL3-expressing tumors (≥50% by IHC) which represented 51% of NECs.
DOI:
10.1200/JCO.2020.38.15_suppl.3552
Trial ID:
Source:
Title:
A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo
Excerpt:
SC16LD6.5 effectively targets and eradicates DLL3-expressing TICs in SCLC and LCNEC PDX tumors and is a promising first-in-class ADC for the treatment of high-grade pulmonary neuroendocrine tumors... DLL3 was identified as >100-fold overexpressed in SCLC and LCNEC PDX versus seven different normal vital organs...SC16LD6.5 offers a therapeutic approach to the treatment of high-grade pulmonary neuroendocrine tumors by delivering a potent cytotoxin specifically to tumor cells and avoiding normal tissues...
DOI:
10.1126/scitranslmed.aac9459
